Cartilage-Derived Angiogenesis Inhibitory Factor

Cartilage-Derived Angiogenesis Inhibitory Factor (CDAIF) is a protein that is known to inhibit angiogenesis, the process through which new blood vessels form from pre-existing vessels. This factor is derived from cartilage, a resilient and smooth elastic tissue, a rubber-like padding that covers and protects the ends of long bones at the joints.

Function

CDAIF functions as an angiogenesis inhibitor, a substance that inhibits the growth of new blood vessels (angiogenesis). It is part of the body's mechanism to control the growth and development of blood vessels. This function is crucial in various physiological and pathological processes such as embryogenesis, tissue repair, tumor growth, and inflammatory diseases.

Role in Disease

The role of CDAIF in disease is complex. It is involved in various pathological conditions where angiogenesis is a critical factor. For instance, in cancer, the growth and spread of tumors often depend on angiogenesis. Therefore, CDAIF, as an angiogenesis inhibitor, can potentially be used in cancer therapy. Similarly, in rheumatoid arthritis, a disease characterized by inflammation and new blood vessel formation, CDAIF may have therapeutic potential.

Research and Therapeutic Potential

Research on CDAIF is ongoing, with scientists exploring its potential therapeutic applications. Given its role in inhibiting angiogenesis, it is being studied for its potential use in treating diseases characterized by excessive angiogenesis, such as cancer and certain eye diseases like macular degeneration.

See Also

• Angiogenesis
• Angiogenesis inhibitor
• Cartilage
• Cancer
• Rheumatoid arthritis

This cartilage-related article is a stub. You can help WikiMD by expanding it.

This arthritis-related article is a stub. You can help WikiMD by expanding it.